Literature DB >> 26270511

Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure.

K Donohoe1, R Levine1,2.   

Abstract

Acquired factor V (FV) inhibitors occur rarely and classically develop after exposure to bovine thrombin. The clinical presentation is variable, ranging from asymptomatic with incidental laboratory abnormalities to significant bleeding. With the development of human-derived thrombin agents, bovine thrombin is less frequently used. We report a case of an acquired FV inhibitor that developed in a patient after exposure to human thrombin used as a hemostatic agent during an otorhinolaryngology surgical procedure. Our review of the literature revealed only one prior reported case of FV inhibitor after exposure to human thrombin. Hematologists and surgeons should be aware of this rare, but potentially life-threatening, complication in the postprocedural setting.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  autoantibodies; bleeding; factor V; hemorrhage; recombinant human thrombin

Mesh:

Substances:

Year:  2015        PMID: 26270511     DOI: 10.1111/jth.13114

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  3 in total

1.  A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Authors:  Hina Ogawa; Masayoshi Souri; Kazunori Kanouchi; Tsukasa Osaki; Rie Ohkubo; Tomoko Kawanishi; Sachiko Wakai; Keita Morikane; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-11-16       Impact factor: 2.490

2.  Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog.

Authors:  Joseph Masciana; Nathan Peterson; John Chretin
Journal:  J Vet Intern Med       Date:  2020-07-20       Impact factor: 3.333

3.  A Case of Acquired Factor V Inhibitor Following Nivolumab Administration.

Authors:  Wataru Kida; Muneo Nakaya; Akiko Ito; Yasuji Kozai; Masato Bingo
Journal:  Cureus       Date:  2022-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.